Amyloidogenic and anti-amyloidogenic properties of presenilin 1.


Journal

Advances in pharmacology (San Diego, Calif.)
ISSN: 1557-8925
Titre abrégé: Adv Pharmacol
Pays: United States
ID NLM: 9015397

Informations de publication

Date de publication:
2021
Historique:
entrez: 12 3 2021
pubmed: 13 3 2021
medline: 10 4 2021
Statut: ppublish

Résumé

Presenilin 1 (PS1) is an intramembrane protease, the active subunit of the γ-secretase complex. Its well-studied function is the amyloidogenic cleavage of the C-terminal fragment of the amyloid precursor protein, also known as C99, to produce the Abeta peptide. Recent findings from the Greengard laboratory suggest that PS1 also have anti-amyloidogenic activities, which reduce Abeta levels. First, it redirects APP-C99 toward autophagic degradation, lowering the amount that can be converted into Abeta. The protein kinase CK1γ2 phosphorylates PS1 at Ser367. Phosphorylated PS1 at this position interacts with Annexin A2, which, in turn, interacts with the lysosomal N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) Vamp8. Annexin A2 facilitates the binding of Vamp8 to the autophagosomal SNARE Syntaxin 17 to modulate the fusion of autophagosomes with lysosomes. Thus, PS1 phosphorylated at Ser367 has an anti-amyloidogenic function, promoting autophagosome-lysosome fusion and increasing C99 degradation. Second, it enhances the ability of microglia to phagocyte and degrade extracellular Abeta oligomer, through regulating the expression of the lysosomal master regulator TFEB. Thus, PS1 has a role in both the production and the clearance of Abeta. Drugs designed to activate CK1γ2 and increase the level of PS1 phosphorylated at Ser367 should be useful in the treatment of Alzheimer's disease.

Identifiants

pubmed: 33706935
pii: S1054-3589(20)30066-1
doi: 10.1016/bs.apha.2020.09.010
pii:
doi:

Substances chimiques

Amyloid 0
Amyloid beta-Peptides 0
Presenilin-1 0
Amyloid Precursor Protein Secretases EC 3.4.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

239-251

Informations de copyright

© 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest No conflicts of interest are noted.

Auteurs

Victor Bustos (V)

Laboratory of Cellular and Molecular Neuroscience, Rockefeller University, New York, NY, United States. Electronic address: vbustos@rockefeller.edu.

Maria V Pulina (MV)

Laboratory of Cellular and Molecular Neuroscience, Rockefeller University, New York, NY, United States.

Jose Ledo (J)

Laboratory of Cellular and Molecular Neuroscience, Rockefeller University, New York, NY, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH